Skip to main content
OpenTrials
Completed

NCT Number: NCT01167972

Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma

The main objective of the study is to determine the proportion of patients with M + mutation status among patients with Non Small Cell Lung Cancer adenocarcinoma.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non Small Cell Lung Cancer Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Abbeville, France

Loading trial locations.

About this study

MSD

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with lung cancer (Non Small Cell Lung Cancer adenocarcinoma)
  • Patient for whom a search for the mutational status of EGFR (EGFR-M +, M- or Mx) has been done or is being analyzed

Exclusion criteria

  • Assessment of mutational status of EGFR is not done

Treatment and study plan

Primary outcomes

  1. The main objective of the study is to determine the proportion of patients with M + mutation status among patients with NSCLC adenocarcinoma

    Time frame: At baseline

Secondary outcomes

  1. Describe the therapeutic management according to the mutational status (EGFR M +, EGFR M- and Mx).

    Time frame: 12 months / At each visit

  2. Describe the therapeutic management of patients with EGFR M +.

    Time frame: 12 months / At each visit

  3. Describe the clinical course of patients EGFR-M +, treated for first-line treatment, and then 2nd line treatment, until 31-AUG-2012

    Time frame: 12 months / At each visit

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

Observational Study on the Management of Patients With Non Small Cell Lung Cancer (NSCLC) Adenocarcinoma Tested for the Activating Mutation of Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR TK)

Acronym: MUTACT

Important dates

Study start
2010
Primary completion
2012
Study completion
2012
First posted
Jul 22, 2010
Registry last updated
Sep 10, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.